Sequelae of Immunocompromised Host Pneumonia.

Benjamin Salwen, Erica Mascarenhas, David J Horne, Kristina Crothers, Jerry S Zifodya

Abstract readReview

In one paragraph

Review in Clinics in chest medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Benjamin SalwenDepartment of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.

Erica MascarenhasDepartment of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.

David J HorneDivision of Pulmonary, Critical Care, & Sleep Medicine, University of Washington, 325 9th Avenue, 359762, Seattle, WA 98104, USA.

Kristina CrothersDivision of Pulmonary, Critical Care, & Sleep Medicine, University of Washington & Veterans Affairs Puget Sound Healthcare System, 1660 South Columbian Way, Seattle, WA 98108, USA.

Jerry S ZifodyaDepartment of Medicine, Section of Pulmonary, Critical Care, & Sleep Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, #8509, New Orleans, LA 70112, USA. Electronic address: jzifodya@tulane.edu.

Funding

Clinical and biologic risk factors for post-tuberculosis lung disease (PTLD) in people with and without HIVK23HL164289 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI Jerry S. Zifodya · 2022 to 2026

$893k

NHLBI NIH HHS K23 HL164289

6 · The paper itself

Abstract

Immunocompromised individuals are at increased risk for opportunistic infections including pneumonia. Pneumonia has long been known to be a leading cause of mortality during induction chemotherapy for acute leukemia and was the first recognized presentation of human immunodeficiency virus (HIV). Even with adequate treatment, there is a wide breadth of postpneumonia sequelae, which is of particular interest in immunocompromised hosts given their increased risk for pneumonia. In this review, we describe the varying complications, presentations, and systems involved in the sequelae of immunocompromised host pneumonia. We focus on people living with HIV, a well-studied heterogenous population, to model immunocompromised hosts.

Indexed as

Immunocompromised HostOpportunistic InfectionsPneumoniaHIV InfectionsHumansHIVImmunocompromised hostPneumoniaSequelaeTuberculosis

Identifiers

PMID39890292

DOI10.1016/j.ccm.2024.10.004

PMCPMC11790256

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.